Login to Your Account



Scil, Pfizer Enter $250M Deal for Preclinical Osteo Drug

By Cormac Sheridan


Thursday, January 17, 2008
Scil Technology GmbH could earn as much as $250 million in up-front and milestone payments from Pfizer Inc. by out-licensing rights to cartilage-derived retinoic acid sensitive protein (CD-RAP), a growth factor preferentially expressed in cartilage tissue. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription